GJ-4 alleviates Aβ_25-35-induced memory dysfunction in mice through protecting the neurovascular unit

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Alzheimer's disease (AD) is a prevalent neurodegenerative disorder with limited therapeutic options.
• GJ-4, derived from Gardenia jasminoides, exhibits neuroprotective properties in AD models, but its mechanisms require elucidation.
• Understanding GJ-4's mechanisms is crucial for developing novel AD treatments.

Purpose of the Study:

• To investigate the mechanism of GJ-4 in an Aβ25-35-induced mouse model of Alzheimer's disease.
• To evaluate GJ-4's effects on spatial learning, memory, and neurovascular unit (NVU) integrity.
• To elucidate the molecular pathways underlying GJ-4's neuroprotective effects.

Main Methods:

• Administered GJ-4 to Aβ25-35-intoxicated mice.
• Assessed spatial learning and memory using behavioral tests.
• Analyzed endothelial function, tight junction protein expression (ZO-1, Claudin-5, Occludin), and inflammatory markers (IL-6, IL-1β, ICAM-1, VCM-1).
• Investigated the HMGB-1/RAGE/NF-κB signaling pathway.

Main Results:

• GJ-4 significantly improved spatial learning and memory in AD mice.
• GJ-4 alleviated endothelial dysfunction by reducing cell edema and enhancing tight junction integrity.
• GJ-4 reduced neuroinflammation by inhibiting glial activation and downregulating inflammatory mediators via the HMGB-1/RAGE/NF-κB pathway.
• GJ-4 modulated the expression of RAGE and LRP-1, suggesting improved endothelial clearance of toxic species.

Conclusions:

• GJ-4 protects the neurovascular unit (NVU) in an Alzheimer's disease model.
• GJ-4's neuroprotective effects are attributed to its ability to attenuate endothelial damage, enhance tight junction function, and inhibit neuroinflammation.
• GJ-4 demonstrates potential as a therapeutic agent for Alzheimer's disease by safeguarding the NVU.